106896-59-7

Usage

Synthesis Reference(s)

Journal of Medicinal Chemistry, 49, p. 2611, 2006 DOI: 10.1021/jm051243a

Upstream product

• 1011-65-0 5-methoxycarbonylindole 
• 75-36-5 acetyl chloride 
• 46064-79-3 2-bromo-5-methoxycarbonylaniline 

Relevant academic research and scientific papers

Synthesis of 3-Substituted Indoles by a Palladium-Assisted Reaction

In the presence of palladium(II) chloride, 2-bromoanilines readily react with the methyl vinyl ketone and the ethyl acrylate to produce vinylogous arylamino ketones and esters.A palladium(0)-assisted cyclization of the arylamino ketones and the esters leads to a formation of 3-substituted indoles.

Rh(III)-Catalyzed [5 + 1] Annulation of Indole-enaminones with Diazo Compounds to Form Highly Functionalized Carbazoles

A novel Rh(III)-catalyzed C-H activation/annulation cascade of indole-enaminones with diazo compounds was reported to construct diversely functionalized carbazole frameworks. The most notable characteristic is that this transformation could smoothly furnish a novel [5 + 1] cyclization product with good to excellent yields (up to 95%), accompanied by the thorough removal of acetyl and N,N-dimethyl groups of two substrates from the target products, rather than the normally expected [4 + 2] cyclization products.

Rhodium(III)-Catalyzed Regioselective Direct C4-Alkylation and C2-Annulation of Indoles: Straightforward Access to Indolopyridone

A straightforward RhIII-catalyzed strategy was developed for the site-selective C4-alkylation and C2-annulation of indole by using electronically variable diazo esters. The transformation was accomplished with the assist of an oxime directing group at the C3 position of the indole core with wide scope and functional-group tolerance. The method directly provided an indolopyridone core. The selectivity was triggered by the reactivity of the diazo coupling partner.

AMIDE COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an amide substituent (R32) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein are capable of reducing the excessive activation of complement.

Design and synthesis of 1-indol-1-yl-propan-2-ones as inhibitors of human cytosolic phospholipase A2α

The synthesis and structure-activity relationship study of a series of 1-indol-1-yl-3-phenoxypropan-2-one inhibitors of cytosolic phospholipase A 2α. (cPLA2α) are described. The compounds were evaluated in a vesicle assay with isolated cPLA2α and in cellular assays with intact human platelets. Systematic variation led to 3-methylhydrogen 1-[3-(4-decyloxyphenoxy)-2-oxopropyl]indole-3,5-dicarboxylate (57), which revealed the highest activity against the isolated enzyme. With an IC50 value of 4.3 nM in this assay, it is one of the most potent in vitro cPLA2α inhibitors known today.

NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVES AS INHIBITORS OF PHOSPHOLIPASE A2

The invention relates to novel heteroaryl-substituted acetone derivatives, which inhibit the enzyme phospholipase A2, to pharmaceutical agents that contain said compounds and to a method for producing said compounds.